Shandong Buchang Pharmaceuticals Co., Ltd.
SSE:603858.SS
16.86 (CNY) • At close June 11, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 11,005.795 | 13,245.133 | 14,951.253 | 15,762.68 | 16,006.714 | 14,255.455 | 13,664.753 | 13,863.919 | 12,320.883 | 11,655.627 | 10,333.616 | 8,591.699 | 7,036.594 | 5,871.833 |
| Cost of Revenue
| 4,427.651 | 4,320.669 | 4,232.51 | 4,132.796 | 3,741.011 | 2,389.146 | 2,351.77 | 2,447.648 | 2,073.264 | 2,005.594 | 2,023.536 | 1,607.997 | 1,329.214 | 1,748.847 |
| Gross Profit
| 6,578.144 | 8,924.464 | 10,718.742 | 11,629.884 | 12,265.704 | 11,866.309 | 11,312.982 | 11,416.27 | 10,247.619 | 9,650.033 | 8,310.08 | 6,983.701 | 5,707.38 | 4,122.986 |
| Gross Profit Ratio
| 0.598 | 0.674 | 0.717 | 0.738 | 0.766 | 0.832 | 0.828 | 0.823 | 0.832 | 0.828 | 0.804 | 0.813 | 0.811 | 0.702 |
| Reseach & Development Expenses
| 345.408 | 476.508 | 284.122 | 408.603 | 533.417 | 505.361 | 480.238 | 489.366 | 397.588 | 278.925 | 232.466 | 165.761 | 0 | 0 |
| General & Administrative Expenses
| 377.367 | 370.737 | 241.689 | 259.797 | 289.093 | 346.608 | 242.254 | 210.344 | 243.199 | 179.342 | 118.084 | 100.604 | 316.486 | 175.992 |
| Selling & Marketing Expenses
| 4,081.563 | 6,109.382 | 7,484.206 | 8,300.369 | 8,373.312 | 8,080.618 | 8,035.787 | 8,287.064 | 6,850.255 | 6,573.045 | 5,972.059 | 4,979.419 | 3,755.9 | 2,445.262 |
| SG&A
| 4,458.93 | 7,372.861 | 7,725.895 | 8,560.166 | 8,662.404 | 8,427.225 | 8,278.041 | 8,497.408 | 7,093.454 | 6,752.387 | 6,090.144 | 5,080.023 | 4,072.386 | 2,621.254 |
| Other Expenses
| 2,020.56 | 639.077 | 795.831 | 695.67 | 603.856 | 475.611 | -15.744 | 202.246 | 132.555 | 162.224 | 251.867 | 175.097 | 250.594 | 270.801 |
| Operating Expenses
| 6,824.898 | 8,488.445 | 8,805.848 | 9,664.439 | 9,799.677 | 9,408.198 | 8,999.476 | 9,620.612 | 8,089.552 | 7,508.173 | 6,651.949 | 5,523.051 | 4,199.989 | 2,708.999 |
| Operating Income
| -246.754 | 436.019 | 1,927.273 | 1,747.709 | 2,365.365 | 2,428.951 | 2,270.344 | 1,758.077 | 1,972.787 | 3,743.63 | 1,557.998 | 1,433.722 | 1,499.299 | 1,393.523 |
| Operating Income Ratio
| -0.022 | 0.033 | 0.129 | 0.111 | 0.148 | 0.17 | 0.166 | 0.127 | 0.16 | 0.321 | 0.151 | 0.167 | 0.213 | 0.237 |
| Total Other Income Expenses Net
| -118.537 | -41.462 | -3,186.662 | -46.607 | -4.671 | -14.238 | -15.744 | 202.246 | 132.337 | 160.431 | 251.737 | 173.557 | 242.923 | 268.838 |
| Income Before Tax
| -365.292 | 394.557 | -1,386.523 | 1,713.703 | 2,360.693 | 2,414.713 | 2,254.6 | 1,960.323 | 2,104.615 | 3,904.061 | 1,809.734 | 1,607.279 | 1,742.222 | 1,662.361 |
| Income Before Tax Ratio
| -0.033 | 0.03 | -0.093 | 0.109 | 0.147 | 0.169 | 0.165 | 0.141 | 0.171 | 0.335 | 0.175 | 0.187 | 0.248 | 0.283 |
| Income Tax Expense
| 337.103 | 242.692 | 331.594 | 478.288 | 517.551 | 451.485 | 347.108 | 321.385 | 334.704 | 370.359 | 300.945 | 259.612 | 283.595 | 273.849 |
| Net Income
| -553.798 | 318.973 | -1,718.117 | 1,162.118 | 1,860.894 | 1,945.997 | 1,888.405 | 1,637.952 | 1,769.365 | 3,536.764 | 1,323.627 | 1,168.575 | 1,251.331 | 1,228.166 |
| Net Income Ratio
| -0.05 | 0.024 | -0.115 | 0.074 | 0.116 | 0.137 | 0.138 | 0.118 | 0.144 | 0.303 | 0.128 | 0.136 | 0.178 | 0.209 |
| EPS
| -0.51 | 0.29 | -1.55 | 1.17 | 1.68 | 1.74 | 1.65 | 1.42 | 1.69 | 3.42 | 1.28 | 1.13 | 1.21 | 83.67 |
| EPS Diluted
| -0.51 | 0.29 | -1.55 | 1.17 | 1.68 | 1.74 | 1.65 | 1.42 | 1.69 | 3.42 | 1.28 | 1.13 | 1.21 | 83.67 |
| EBITDA
| 382.613 | 1,096.216 | -610.529 | 2,264.29 | 2,920.032 | 2,881.882 | 2,653.182 | 2,259.571 | 2,560.494 | 4,156.47 | 1,956.525 | 1,695.04 | 1,507.391 | 1,423.491 |
| EBITDA Ratio
| 0.035 | 0.083 | -0.041 | 0.144 | 0.182 | 0.202 | 0.194 | 0.163 | 0.208 | 0.357 | 0.189 | 0.197 | 0.214 | 0.242 |